ALPS Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

ALPS Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-5,629	Closed	-$113K	–	993
2023 Q3	$113K	Buy	5,629 +42	+0.8%	+$943	﹤0.01%	968
2023 Q2	$150K	Buy	+5,587	New	+$241K	﹤0.01%	981
2020 Q4	–	Sell	-6,247	Closed	-$1.37M	–	863
2020 Q3	$1.37M	Sell	6,247 -403	-6%	-$98.6K	0.02%	287
2020 Q2	$1.89M	Buy	+6,650	New	+$1.97M	0.03%	244
2016 Q2	–	Sell	-2,679	Closed	-$358K	–	630
2016 Q1	$358K	Sell	2,679 -459	-15%	-$50.7K	﹤0.01%	572
2015 Q4	$624K	Sell	3,138 -587	-16%	-$127K	0.01%	254
2015 Q3	$5.88K	Buy	3,725 +1,363	+58%	+$365K	0.01%	245
2015 Q2	$964K	Buy	2,362 +1,182	+100%	+$511K	0.01%	215
2015 Q1	$542K	Buy	+1,180	New	+$509K	﹤0.01%	322

Other funds holding KPTI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

ALPS Advisors's KPTI Position: Q4 2023 in Review

ALPS Advisors sold out of Karyopharm Therapeutics (KPTI) in Q4 2023, closing a stake of 5,629 shares — an estimated $113K sold.

ALPS Advisors first reported a position in KPTI in Q1 2015 and held it in 9 quarters. The position peaked at $1.89M in Q2 2020. 117 funds tracked by Wall St. Rank hold KPTI as of Q4 2023.

ALPS Advisors reported no remaining Karyopharm Therapeutics position as of Q4 2023 after selling out during the quarter.
ALPS Advisors sold 5,629 Karyopharm Therapeutics shares in Q4 2023, an estimated $113K.
ALPS Advisors first reported a position in Karyopharm Therapeutics in Q1 2015 and held it in 9 quarters.
ALPS Advisors's Karyopharm Therapeutics position peaked at $1.89M in Q2 2020.
117 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2023.

Based on ALPS Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.